Meeting
2018 ASCO Annual Meeting
A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).
Authors
Heather L. McArthur
Cedars-Sinai Medical Center, Los Angeles, CA
Heather L. McArthur , Christopher Andrew Barker , Ayca Gucalp , Lizza Lebron-Zapata , Yong Hannah Wen , Cindy Kallman , Alessandro D'Agnolo , Micaela Rodine , Brittany Arnold , Zhigang Zhang , Alice Y. Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02730130
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1017)
DOI
10.1200/JCO.2018.36.15_suppl.1017
Abstract #
1017
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).
First Author: Heather L. McArthur
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho
Poster
2021 ASCO Annual Meeting
A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).
First Author: Kai Sun
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula